This clinical trial is focused on studying the effects of a treatment for patients who are hospitalized due to a severe viral lung infection and require extra oxygen to help them breathe. The treatment being tested is called Tozorakimab, also known by its code name MEDI3506. It is a solution that is given through an injection into the veins. The study will compare the effects of Tozorakimab with a placebo to see how well it works in preventing serious outcomes like death or the need for advanced breathing support by Day 28 of the study.
The purpose of this study is to evaluate the safety and effectiveness of Tozorakimab in helping patients recover from severe viral lung infections. Participants in the study will receive either the Tozorakimab treatment or a placebo, in addition to the standard care they are already receiving. The study will monitor the participants over a period of time to see how many days they are alive and free from needing intensive care or extra oxygen, as well as other health outcomes.
Throughout the study, researchers will collect information on various health measures, such as the number of days participants are alive and not in the intensive care unit, and the time it takes for them to recover enough to stop needing extra oxygen. The study aims to provide valuable insights into how Tozorakimab can help improve the health and recovery of patients with severe viral lung infections.
1enrollment
Upon joining the study, eligibility is confirmed based on specific criteria. Participants must be adults aged 18 or older, hospitalized with a viral lung infection, and require supplemental oxygen due to low blood oxygen levels.
2randomization
Participants are randomly assigned to receive either tozorakimab or a placebo. This process is double-blind, meaning neither the participants nor the researchers know who receives the actual medication.
3treatment administration
Tozorakimab is administered as a solution for injection through an intravenous route. The frequency and dosage are determined by the study protocol and are administered by healthcare professionals.
4monitoring and assessments
Participants are monitored for 28 days to evaluate the effect of the treatment. The primary focus is on preventing death or the need for advanced respiratory support, such as mechanical ventilation or extracorporeal membrane oxygenation (ECMO).
Secondary assessments include survival rates up to 60 days, time spent outside the intensive care unit (ICU), and days without the need for supplemental oxygen.
5follow-up
Participants continue to be observed for any long-term effects or outcomes related to the treatment. This includes tracking survival rates, time to discharge, and any development of antibodies against the drug.
Who Can Join the Study?
Participants must be 18 years or older at the time they sign the consent form.
Participants must be hospitalized due to a viral lung infection.
Participants must have low oxygen levels in their blood, which requires treatment with extra oxygen. Low oxygen levels are defined as:
Blood oxygen saturation (SpO2) of 90% or less, or
Blood oxygen saturation (SpO2) of 92% or less along with one or both of the following:
Chest X-ray or CT scan showing signs of a viral lung infection, as judged by the doctor.
Using extra muscles to breathe or having a breathing rate of more than 22 breaths per minute.
Participants must still have low oxygen levels at the time they are randomly assigned to a treatment group, requiring extra oxygen treatment.
Who Cannot Join the Study?
Patients with severe viral lung infections cannot participate. This means if you have a serious infection in your lungs caused by a virus, you are not eligible.
Patients who do not require supplemental oxygen are excluded. This means if you do not need extra oxygen to help you breathe, you cannot join the study.
Patients who are already on IMV/ECMO are not eligible. IMV stands for invasive mechanical ventilation, which is a machine that helps you breathe. ECMO stands for extracorporeal membrane oxygenation, which is a machine that helps your heart and lungs work.
Tozorakimab (MEDI3506) is a medication being studied for its potential to help patients who are hospitalized with viral lung infections and need extra oxygen. The goal of using this medication is to see if it can prevent the patient’s condition from getting worse, such as needing a machine to help them breathe or preventing death within 28 days of treatment.
Severe viral lung infections – These infections occur when viruses invade the lungs, leading to inflammation and difficulty in breathing. The condition can cause symptoms such as coughing, fever, and shortness of breath. As the infection progresses, it may result in the need for supplemental oxygen to maintain adequate oxygen levels in the blood. In severe cases, the infection can lead to respiratory failure, requiring mechanical ventilation or extracorporeal membrane oxygenation (ECMO) to support breathing. The progression of the disease can vary, with some individuals experiencing rapid deterioration. The severity of the infection often depends on the type of virus and the individual’s overall health.
The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Belgium 
Bulgaria 
Czechia 
Denmark 
France 
Germany 
Greece 
Hungary 
Italy 
Poland 
Romania 
Slovakia 
Spain 
Sweden